+

WO2000018961A3 - Analyse de l'expression d'acides nucleiques et de polypeptides specifiques utiles pour le diagnostic et le traitement du cancer de la prostate - Google Patents

Analyse de l'expression d'acides nucleiques et de polypeptides specifiques utiles pour le diagnostic et le traitement du cancer de la prostate Download PDF

Info

Publication number
WO2000018961A3
WO2000018961A3 PCT/US1999/022535 US9922535W WO0018961A3 WO 2000018961 A3 WO2000018961 A3 WO 2000018961A3 US 9922535 W US9922535 W US 9922535W WO 0018961 A3 WO0018961 A3 WO 0018961A3
Authority
WO
WIPO (PCT)
Prior art keywords
hrpca
prostate cancer
androgen
treatment
diagnosis
Prior art date
Application number
PCT/US1999/022535
Other languages
English (en)
Other versions
WO2000018961A2 (fr
Inventor
Kyle J Macbeth
Andrew W Shyjan
Original Assignee
Millennium Pharm Inc
Kyle J Macbeth
Andrew W Shyjan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/163,759 external-priority patent/US6872811B1/en
Application filed by Millennium Pharm Inc, Kyle J Macbeth, Andrew W Shyjan filed Critical Millennium Pharm Inc
Priority to AU65021/99A priority Critical patent/AU6502199A/en
Priority to EP99952976A priority patent/EP1117836A2/fr
Priority to JP2000572408A priority patent/JP2002531061A/ja
Priority to CA002344550A priority patent/CA2344550A1/fr
Publication of WO2000018961A2 publication Critical patent/WO2000018961A2/fr
Publication of WO2000018961A3 publication Critical patent/WO2000018961A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention se fonde partiellement sur la découverte d'un certain nombre de gènes (HRPCa 2, HRPCa 3, HRPCa 6/7, HRPCa 8, HRPCa 9, HRPCa 10, HRPCa 13, HRPCa 14, HRPCa 15 et HRPCa 19) qui sont inductibles par des androgènes dans les cellules du cancer de la prostate dépendantes des androgènes (par exemple, les cellules LNCaP) et exprimés de façon constitutive dans les cellules du cancer de la prostate indépendantes des androgènes (par exemple, les cellules LN3 LNCaP). Etant donné que les androgènes sont nécessaires à la croissance et à la survie des cellules du cancer de la prostate dépendantes des androgènes HRPCa 2, HRPCa 3, HRPCa 6/7, HRPCa 8, HRPCa 9, HRPCa 10, HRPCa 13, HRPCa 14, HRPCa 15 et HRPCa 19 constituent des cibles thérapeutiques. Un agent qui diminue l'expression ou l'activité de HRPCa 2, HRPCa 3, HRPCa 6/7, HRPCa 8, HRPCa 9, HRPCa 10, HRPCa 13, HRPCa14, HRPCa 15 ou HRPCa 19 peut ralentir ou stopper la croissance des cellules du cancer de la prostate ou peut tuer lesdites cellules du cancer de la prostate. En outre, du fait que les gènes selon l'invention sont exprimés de façon constitutive par des cellules du cancer de la prostate indépendantes des androgènes, ces gènes peuvent servir à identifier les agents utiles pour le traitement du cancer de la prostate, qu'il soit dépendant ou indépendant des androgènes.
PCT/US1999/022535 1998-09-30 1999-09-30 Analyse de l'expression d'acides nucleiques et de polypeptides specifiques utiles pour le diagnostic et le traitement du cancer de la prostate WO2000018961A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU65021/99A AU6502199A (en) 1998-09-30 1999-09-30 Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EP99952976A EP1117836A2 (fr) 1998-09-30 1999-09-30 Analyse de l'expression d'acides nucleiques et de polypeptides specifiques utiles pour le diagnostic et le traitement du cancer de la prostate
JP2000572408A JP2002531061A (ja) 1998-09-30 1999-09-30 前立腺癌の診断および治療において有用な特異的核酸およびポリペプチドの発現解析
CA002344550A CA2344550A1 (fr) 1998-09-30 1999-09-30 Analyse de l'expression d'acides nucleiques et de polypeptides specifiques utiles pour le diagnostic et le traitement du cancer de la prostate

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16415998A 1998-09-30 1998-09-30
US09/164,159 1998-09-30
US09/163,759 US6872811B1 (en) 1998-09-30 1998-09-30 HRPCa9 and HRPCa10 nucleic acids and polypeptides
US09/163,759 1998-10-30

Publications (2)

Publication Number Publication Date
WO2000018961A2 WO2000018961A2 (fr) 2000-04-06
WO2000018961A3 true WO2000018961A3 (fr) 2001-03-08

Family

ID=26859918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/022535 WO2000018961A2 (fr) 1998-09-30 1999-09-30 Analyse de l'expression d'acides nucleiques et de polypeptides specifiques utiles pour le diagnostic et le traitement du cancer de la prostate

Country Status (5)

Country Link
EP (1) EP1117836A2 (fr)
JP (1) JP2002531061A (fr)
AU (1) AU6502199A (fr)
CA (1) CA2344550A1 (fr)
WO (1) WO2000018961A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960474B2 (en) 2000-06-28 2005-11-01 Bristol-Myers Squibb Company Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
ATE413466T1 (de) 1998-09-02 2008-11-15 Diadexus Inc Verfahren zur diagnose, bewertung sowie bilddarstellung verschiedener krebserkrankungen
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6355430B1 (en) 1998-12-24 2002-03-12 Millennium Pharmaceuticals, Inc. Diagnostic and screening methods employing KIAA0101
AU4484400A (en) * 1999-04-23 2000-11-10 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
EP1299727B1 (fr) * 2000-07-12 2009-04-22 Agensys, Inc. Nouvel antigene tumoral utile dans le diagnostic et le traitement de cancers de la vessie, de l'ovaire, du poumon et du rein
CA2429749A1 (fr) 2000-11-28 2002-06-06 Wyeth Analyse d'expression d'acides nucleiques kiaa et polypeptides utilises dans le diagnostic et le traitement du cancer de la prostate
MXPA03004688A (es) 2000-11-28 2003-09-05 Wyeth Corp Analisis de expresion de acidos nucleicos y polipeptidos fkbp utiles en diagnostico.
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
DE06814528T1 (de) 2005-09-12 2012-01-05 The Regent Of The University Of Michigan Wiederkehrende genfusionen bei prostatakrebs
JP5433572B2 (ja) 2007-07-06 2014-03-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｉｐｏｌ１−ｅｔｖ１遺伝子再編成
WO2009020521A2 (fr) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification et traitement de tumeurs de la prostate répondant aux œstrogènes
JP5800817B2 (ja) 2009-09-17 2015-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
JP2012196211A (ja) * 2012-04-10 2012-10-18 Japan Science & Technology Agency 前立腺癌マーカポリペプチド、該ポリペプチドに対する抗体、及び該ポリペプチドを利用した前立腺癌の診断方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028498A1 (fr) * 1994-04-15 1995-10-26 The Trustees Of Columbia University In The City Of New York Procede de d'evaluation au niveau moleculaire des stades d'evolution du cancer de la prostate
WO1997027317A1 (fr) * 1996-01-23 1997-07-31 Affymetrix, Inc. Evaluation rapide de difference d'abondance d'acides nucleiques, avec un systeme d'oligonucleotides haute densite
WO1997036535A2 (fr) * 1996-03-29 1997-10-09 Board Of Regents, The University Of Texas System Biomarqueurs servant a effectuer la detection, le diagnostic et le pronostic du cancer de la prostate
WO1998004689A1 (fr) * 1995-07-31 1998-02-05 Urocor, Inc. Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate
WO1998005797A1 (fr) * 1996-08-06 1998-02-12 Cell Genesys, Inc. Criblage de medicaments du cancer de la prostate
US5786362A (en) * 1994-06-16 1998-07-28 University Of Miami Method of treating Hormone independent cancer
WO1998039447A1 (fr) * 1997-03-07 1998-09-11 Diagnostic Products Corporation Marqueur specifique au cancer de la prostate

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028498A1 (fr) * 1994-04-15 1995-10-26 The Trustees Of Columbia University In The City Of New York Procede de d'evaluation au niveau moleculaire des stades d'evolution du cancer de la prostate
US5786362A (en) * 1994-06-16 1998-07-28 University Of Miami Method of treating Hormone independent cancer
WO1998004689A1 (fr) * 1995-07-31 1998-02-05 Urocor, Inc. Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate
WO1997027317A1 (fr) * 1996-01-23 1997-07-31 Affymetrix, Inc. Evaluation rapide de difference d'abondance d'acides nucleiques, avec un systeme d'oligonucleotides haute densite
WO1997036535A2 (fr) * 1996-03-29 1997-10-09 Board Of Regents, The University Of Texas System Biomarqueurs servant a effectuer la detection, le diagnostic et le pronostic du cancer de la prostate
WO1998005797A1 (fr) * 1996-08-06 1998-02-12 Cell Genesys, Inc. Criblage de medicaments du cancer de la prostate
WO1998039447A1 (fr) * 1997-03-07 1998-09-11 Diagnostic Products Corporation Marqueur specifique au cancer de la prostate

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BIECHE I ET AL: "Overexpression of the stathmin gene in a subset of human breast cancer.", BRITISH JOURNAL OF CANCER, vol. 78, no. 6, 1998, pages 701 - 709, XP000939150, ISSN: 0007-0920 *
BLOK L J ET AL: "ISOLATION OF CDNAS THAT ARE DIFFERENTIALLY EXPRESSED BETWEEN ANDROGEN-DEPENDENT AND ANDROGEN-INDEPENDENT PROSTATE CARCINOMA CELLS USING DIFFERENTIAL DISPLAY PCR", PROSTATE,US,WILEY-LISS, NEW YORK, NY, vol. 26, no. 4, 1 April 1995 (1995-04-01), pages 213 - 224, XP000611577, ISSN: 0270-4137 *
CHANG GLENN T G ET AL: "Differentially expressed genes in androgen-dependent and -independent prostate carcinomas.", CANCER RESEARCH, vol. 57, no. 18, 1997, pages 4075 - 4081, XP002147425, ISSN: 0008-5472 *
DELWORTH MARK G ET AL: "Systemic administration of 4-amidinoindanon-1-(2'-amidino)-hydrazone, a new inhibitor of S-adenosylmethionine decarboxylase, produces cytostasis of human prostate cancer in athymic nude mice.", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 6, no. 2, 1995, pages 293 - 299, XP000946083, ISSN: 1019-6439 *
FRIEDRICH ET AL.: "DIFFERENTIATION-STAGE SPECIFIC EXPRESSION OF ONCOPROTEIN 18 IN HUMAN AND RAT PROSTATIC ADENOCARCINOMA", THE PROSTATE, vol. 27, 1995, pages 102 - 109, XP000938476 *
GREGORY ET AL.: "ANDROGEN RECEPTOR EXPRESSION IN ANDROGEN-INDEPENDENT PROSTATE CANCER IS ASSOCIATED WITH INCREASED EXPRESSION OF ANDROGEN-REGULATED GENES", CANCER RESEARCH, vol. 58, December 1998 (1998-12-01), pages 5718 - 5724, XP002147396 *
JORDAN MARY ANN ET AL: "Microtubules and actin filaments: Dynamic targets for cancer chemotherapy.", CURRENT OPINION IN CELL BIOLOGY, vol. 10, no. 1, February 1998 (1998-02-01), pages 123 - 130, XP000939151, ISSN: 0955-0674 *
PRASAD ET AL.: "DIFFERENTIAL EXPRESSION OF STATHMIN DURING NEOPLASTIC CONVERSION OF HUMAN PROSTATE EPITHELIAL CELLS IS REVERSED BY HYPOMETHYLATING AGENT, 5-AZACYTIDINE", INT.J.ONCOLOGY, vol. 14, March 1999 (1999-03-01), pages 529 - 534, XP000939152 *
ROBSON C N ET AL: "IDENTIFICATION OF PROSTATIC ANDROGEN REGULATED GENES USING THE DIFFERENTIAL DISPLAY TECHNIQUE", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH,US,PHILADELPHIA, AACR, vol. MEETING 86, 18 March 1995 (1995-03-18), pages 266, XP002019344, ISSN: 0197-016X *
YANG ET AL.: "IDENTIFICATION OF GENES EXPRESSED DIFFERENTIALLY BY LNCaP OR PC-3 PROSTATE CANCER CELL LINES", CANCER RESEARCH, vol. 58, August 1998 (1998-08-01), pages 3732 - 3735, XP002147395 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960474B2 (en) 2000-06-28 2005-11-01 Bristol-Myers Squibb Company Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator

Also Published As

Publication number Publication date
AU6502199A (en) 2000-04-17
CA2344550A1 (fr) 2000-04-06
JP2002531061A (ja) 2002-09-24
EP1117836A2 (fr) 2001-07-25
WO2000018961A2 (fr) 2000-04-06

Similar Documents

Publication Publication Date Title
WO2000018961A3 (fr) Analyse de l'expression d'acides nucleiques et de polypeptides specifiques utiles pour le diagnostic et le traitement du cancer de la prostate
MXPA02006145A (es) Metodo para el aislamiento de arn de especimenes de tejido incluido en parafina fijo en formalina.
CA2199117A1 (fr) Composes et procedes de traitement du cancer
WO2001051633A3 (fr) Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate
WO2001073032A3 (fr) Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2001034802A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer de la prostate
WO1998019167A3 (fr) Gene de classe i du complexe majeur d'histocompatibilite humain a stress cellulaire regule
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
WO2002099075A3 (fr) Prmt comme modificateurs de la voie p53 et methodes d'utilisation
PT1053313E (pt) Oligonucleotidos ''antisense'' optimizados complementares de sequencias de dna metiltransferase
MX9801264A (es) Control de la expresion del gen de cd44 para uso terapeutico.
ES2187648T3 (es) Metodo para la administracion de farmacos para terapia genica.
WO2002090925A3 (fr) Polypeptides acides nucleiques associes au cancer
WO2001044282A3 (fr) Polypeptides bcl-g, acides nucleique de codage et leurs procedes d'utilisation
AU5913696A (en) Methods and uses for apoptin
MXPA03000979A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
AP2781A (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof
WO2000004153A3 (fr) Inhibition de la transformation cellulaire par la proteine pea3 humaine
WO1998051782A3 (fr) 3-hydroxyisobutyryl-coenzyme a hydrolase humaine
AU3282300A (en) Molecules for the treatment and diagnosis of tumors
WO1999050671A3 (fr) Proteine toso comme cible de criblage de medicaments
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor
WO2002062204A3 (fr) Methodes de diagnostic et de traitement des maladies cardiaques
WO2000058506A3 (fr) Depistage d'une predisposition au psoriasis

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 65021

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2344550

Country of ref document: CA

Ref country code: CA

Ref document number: 2344550

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999952976

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 572408

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999952976

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09806428

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999952976

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载